Mitophagy is a specialized form of selective autophagy that mediates the targeted degradation of damaged or dysfunctional mitochondria[^1]. This process is critical for maintaining mitochondrial quality control, particularly in post-mitotic cells such as neurons that cannot dilute damaged components through cell division[^2]. The term mitophagy was coined in 2005 by John Lemasters to describe this selective autophagic process[^3].
In the context of neurodegenerative diseases, mitophagy plays a particularly important role due to the high energy demands of neurons, their long lifespan, and the accumulation of mitochondrial damage over decades[^4]. Impairment of mitophagy pathways has been strongly implicated in both Alzheimer's disease (AD) and Parkinson's disease (PD), making this mechanism a key therapeutic target[^5].
The canonical mitophagy pathway involves the coordinated action of PINK1 (PTEN-induced kinase 1) and Parkin (PRKN), two proteins whose dysfunction is directly linked to familial Parkinson's disease[^6]:
-
PINK1 stabilization: Under normal conditions, PINK1 is imported into mitochondria and degraded by proteases. Upon mitochondrial damage (loss of membrane potential, oxidative stress, DNA damage), PINK1 accumulates on the outer mitochondrial membrane[^7].
-
Parkin recruitment: PINK1 phosphorylates both ubiquitin (at Ser65) and Parkin (at multiple sites), activating Parkin's E3 ubiquitin ligase activity[^8].
-
Ubiquitin chain formation: Activated Parkin ubiquitinates proteins on the outer mitochondrial membrane, creating polyubiquitin chains that serve as recognition signals for autophagy receptors[^9].
-
Autophagy receptor binding: Autophagy receptors including p62/SQSTM1, OPTN (optineurin), and NDP52 bind to ubiquitinated mitochondria through their ubiquitin-binding domains while simultaneously engaging LC3 on the growing autophagosome through LIR (LC3-interacting region) motifs[^10].
-
Autophagosome formation: The expanding isolation membrane (phagophore) engulfs the damaged mitochondrion, guided by the receptor-ubiquitin-LC3 complex[^11].
-
Lysosomal fusion: The autophagosome fuses with lysosomes, with the aid of proteins such as VAMP8 and STX17, resulting in mitochondrial degradation[^12].
Alternative, PINK1/Parkin-independent pathways exist:
BNIP3/NIX pathway: BNIP3 (BCL2/adenovirus E1B 19kDa interacting protein 3) and its homolog NIX serve as direct mitophagy receptors. These proteins are localized to the outer mitochondrial membrane and can directly bind LC3 through their LIR domains, bypassing the need for ubiquitination[^13]. This pathway is particularly important during reticulocyte maturation and hypoxia[^14].
FUNDC1 pathway: FUNDC1 (FUN14 domain containing 1) is a mitochondrial outer membrane protein that acts as a receptor for hypoxia-induced mitophagy. Under hypoxic conditions, FUNDC1 is phosphorylated by Src kinase and recruits LC3 for mitophagic degradation[^15].
Cardiolipin-mediated recognition: Cardiolipin, a phospholipid normally located in the inner mitochondrial membrane, can externalize to the outer membrane during mitochondrial damage. Externalized cardiolipin directly binds LC3 and serves as an eat-me signal for mitophagy[^16].
Neurons exhibit unique vulnerabilities that make mitophagy particularly critical:
-
High energy demands: The brain represents only 2% of body weight but consumes approximately 20% of oxygen and 25% of glucose, with mitochondria being central to ATP production[^17].
-
Post-mitotic nature: Unlike most cells, neurons cannot undergo cell division, meaning damaged mitochondria accumulate over the entire lifespan of the cell[^18].
-
Axonal mitochondrial dynamics: Neurons require active transport of mitochondria along axons to regions with high energy demand (synapses, nodes of Ranvier). Mitophagy must occur both in the soma and distally in axons, requiring coordinated autophagic machinery[^19].
-
Synaptic mitochondria: Synaptic terminals are particularly vulnerable to mitochondrial dysfunction due to high local energy requirements for neurotransmitter release and recycling[^20].
Recent research has identified a dedicated pathway for mitophagy in neurons:
-
Damage sensing: Mitochondrial damage in axons triggers PINK1 accumulation on distal mitochondria[^21].
-
Retrograde transport: Damaged mitochondria are retrogradely transported toward the soma via dynein motors, carrying Parkin and autophagy receptors[^22].
-
Somatic degradation: Upon reaching the soma, mitochondria undergo complete mitophagic degradation in the lysosomal-rich cell body[^23].
In Alzheimer's disease, multiple mechanisms impair mitophagy:
-
Amyloid-β effects: Amyloid-β oligomers directly impair mitophagy, leading to accumulation of dysfunctional mitochondria[^24].
-
Tau pathology: Hyperphosphorylated tau disrupts mitochondrial transport and mitophagy, creating a vicious cycle[^25].
-
PINK1/Parkin downregulation: PINK1 and Parkin expression are reduced in AD brains, compromising the canonical mitophagy pathway[^26].
-
Lysosomal dysfunction: AD-associated lysosomal impairment prevents effective degradation of mitophagic cargo[^27].
Evidence from studies:
- PINK1 and Parkin levels are significantly decreased in AD patient brains compared to age-matched controls[^28].
- Amyloid-β treatment in neuronal cultures leads to impaired PINK1 accumulation on damaged mitochondria[^29].
- Enhancing mitophagy through genetic or pharmacological approaches reduces amyloid pathology and improves cognitive function in animal models[^30].
Parkinson's disease provides the strongest genetic link to mitophagy dysfunction:
-
PINK1 mutations: Loss-of-function mutations in PINK1 impair the initiation of mitophagy, leading to accumulation of damaged mitochondria[^31].
-
Parkin mutations: Mutations in PRKN (encoding Parkin) prevent ubiquitination of damaged mitochondria, blocking mitophagy execution[^32].
-
α-Synuclein interference: Wild-type α-synuclein can inhibit mitophagy, and mutant forms (A53T, A30P) exacerbate this effect[^33].
-
Mitochondrial complex I deficiency: PD-associated complex I dysfunction creates excessive mitochondrial damage that overwhelms the mitophagy system[^34].
Evidence from studies:
- PINK1 knockout mice exhibit enhanced sensitivity to mitochondrial toxins and show progressive dopaminergic neuron loss[^35].
- Parkin-deficient flies and mice show accumulation of abnormal mitochondria and progressive neurodegeneration[^36].
- Induced pluripotent stem cell (iPSC)-derived dopaminergic neurons from PINK1 mutation carriers show impaired mitophagy and increased sensitivity to mitochondrial stress[^37].
Mitophagy dysfunction contributes to ALS pathogenesis[^38]:
- SOD1 mutations: Disrupt mitochondrial quality control
- C9orf72 hexanucleotide expansion: Impairs autophagy-lysosome pathway
- TDP-43 aggregation: Disrupts autophagy machinery
- OPTN mutations: Cause familial ALS
Mitochondrial dysfunction is a hallmark of HD[^39]:
- Mutant huntingtin: Impairs PINK1/Parkin function
- Mitochondrial fragmentation: Enhanced fission, reduced fusion
- Metabolic deficits: Reduced mitochondrial respiration
The PINK1 gene on chromosome 6q21 encodes a serine/threonine-protein kinase essential for mitophagy initiation[^40]. Over 70 pathogenic mutations have been identified, predominantly causing autosomal recessive young-onset Parkinson's disease (AR-JP). These mutations affect:
- Kinase domain: Impairs catalytic activity
- Mitochondrial targeting: Disrupts proper mitochondrial localization
- Protein stability: Reduces PINK1 protein levels
The PRKN gene encodes an E3 ubiquitin ligase with critical roles in mitochondrial quality control[^41]. Recessive mutations cause approximately 50% of AR-JP cases:
- RING domain mutations: Impair ubiquitin ligase activity
- Ubiquitin-like domain mutations: Affect substrate recognition
- Deletions: Cause complete loss of function
¶ OPTN and TBK1
OPTN mutations: Cause both familial PD and ALS[^42]
- Disrupts autophagy receptor function
- Impairs clearance of damaged mitochondria
TBK1 mutations: Associated with ALS and FTD[^43]
- Essential for mitophagy receptor function
- Affects OPTN and p62 phosphorylation
Mitophagy-related genes are under complex transcriptional regulation[^44]:
- PGC-1α: Master regulator of mitochondrial biogenesis, also influences mitophagy
- TFEB: Lysosomal biogenesis master regulator, promotes mitophagy
- FOXO transcription factors: Regulate autophagy genes
Phosphorylation plays critical roles in mitophagy regulation[^45]:
- PINK1 autophosphorylation: Activates kinase function
- Parkin phosphorylation: Required for E3 ligase activation
- Ubiquitin phosphorylation: Creates phospho-ubiquitin recognition signal
- OPTN phosphorylation: Enhances autophagy receptor function
MicroRNAs regulate mitophagy[^46]:
- miR-27a/b: Target PINK1 and DRP1
- miR-124: Regulates mitochondrial function
- miR-137: Modulates PINK1 expression
¶ Mitochondrial Dynamics and Mitophagy
¶ Fusion and Fission Balance
Mitochondrial dynamics critically influence mitophagy efficiency[^47]:
Fusion proteins:
- Mfn1/Mfn2: Outer membrane fusion
- OPA1: Inner membrane fusion
Fission proteins:
- DRP1: Main fission GTPase
- Fis1: Outer membrane fission adaptor
- Fusion promotes survival: Connected mitochondria share components, diluting damage
- Fission isolates damaged segments: Allows selective removal of dysfunctional mitochondria[^48]
- Excessive fission: Impairs mitophagy, leads to mitochondrial fragmentation
- Excessive fusion: Prevents segregation of damaged mitochondria
AMP-activated protein kinase (AMPK) senses cellular energy status and regulates mitophagy[^49]:
- Low ATP/High AMP: Activates AMPK
- AMPK activation: Inhibits mTORC1, promotes TFEB nuclear translocation
- Direct phosphorylation: AMPK phosphorylates PINK1 and autophagy proteins
The mechanistic target of rapamycin complex 1 (mTORC1) negatively regulates mitophagy[^50]:
- Nutrient abundance: mTORC1 active, inhibits autophagy
- Nutrient deprivation: mTORC1 inhibition permits autophagy
- Rapamycin treatment: Induces mitophagy through mTORC1 inhibition
Urolithin A: This gut-derived metabolite from ellagitannins is the most clinically advanced mitophagy activator. It enhances mitophagy through:
- Inhibition of mitochondrial fission (via Drp1 modulation)
- Promotion of mitochondrial fusion (via Mfn1/2, OPA1)
- Enhanced autophagic flux (increased LC3 lipidation)
- Improvement in PINK1/Parkin pathway activity
Phase III clinical trials have demonstrated safety and efficacy in improving mitochondrial function in humans[^51].
Other compounds:
- Nilotinib: Tyrosine kinase inhibitor shown to enhance mitophagy
- Rapamycin: mTOR inhibitor that induces autophagy
- AICAR: AMPK activator that stimulates autophagy
- Acetyl-DL-leucine: Shown to improve mitophagy in models
- PINK1 gene therapy: Viral delivery of PINK1 to restore mitophagy function
- Parkin overexpression: Enhancing Parkin-mediated ubiquitination
- Autophagy receptor optimization: Enhancing p62, OPTN, or NDP52 function
Several trials are targeting mitophagy in neurodegeneration[^52]:
- Urolithin A: Phase III completed for muscle function
- Rapamycin: Trials in AD and PD
- Nilotinib: Phase II in PD/PD with dementia
In blood:
- Mitochondrial DNA (mtDNA): Circulating mtDNA as damage marker
- Cell-free mtDNA: Elevated in neurodegeneration
- Mitophagy proteins: p62, LC3 in circulating cells
In CSF:
- p-tau/total tau ratio: Correlates with mitophagy status
- Mitochondrial proteins: DJ-1, PINK1 levels
- PET tracers: Mitochondrial function tracers
- MRI: Magnetic resonance spectroscopy for mitochondrial metabolites
- Near-infrared spectroscopy: Cerebral oxygen metabolism
PINK1 knockout mice:
- Mild phenotype without stressors
- Enhanced sensitivity to mitochondrial toxins
- Impaired mitophagy response[^53]
Parkin knockout mice:
- More severe phenotype than PINK1-/-
- Accumulation of damaged mitochondria
- Dopaminergic neuron loss with age
Compound models:
- PINK1/Parkin double knockout: Severe neurodegeneration
- Mitochondrial dynamics mutants: Synergistic effects
- MPTP: Induces mitophagy impairment
- 6-OHDA: Dopaminergic neuron loss
- Rotenone: Complex I inhibition
Mitophagy coordinates with mitochondrial biogenesis[^54]:
- PGC-1α: Regulates both processes
- TFEB: Master regulator of lysosomal and mitochondrial biogenesis
- Balanced regulation: Prevents mitochondrial depletion
The ubiquitin-proteasome system works with mitophagy[^55]:
- Ubiquitin chains: Shared degradation signals
- p62/SQSTM1: Links ubiquitination to autophagy
- Proteasome inhibitors: May induce compensatory mitophagy
Mitochondrial UPR (UPRmt) interacts with mitophagy[^56]:
- ATF4: Regulates mitophagy genes during stress
- CHOP: Pro-apoptotic in severe stress
- Integrated stress response: Coordinates quality control
The substantia nigra pars compacta shows particular vulnerability in PD[^57]:
- High metabolic demands: Dopaminergic neurons have high energy requirements
- Iron accumulation: Promotes oxidative stress
- Complex morphology: Extensive axonal arborization
- PINK1/Parkin deficiency: Severely reduced mitophagy capacity
The hippocampus is critically affected in AD[^58]:
- CA1 pyramidal neurons: Early tau pathology
- Synaptic plasticity: High energy demands for LTP
- Memory consolidation: Affected by mitophagy decline
The frontal cortex shows progressive dysfunction with age and disease[^59]:
- Executive function impairment: Associated with mitophagy failure
- Layer V pyramidal neurons: Earliest changes
- White matter oligodendrocytes: Also affected
¶ Key Proteins and Genes
| Protein/Gene |
Function |
Disease Link |
| PINK1 |
Kinase that initiates mitophagy |
PD (AR-JP) |
| PRKN (Parkin) |
E3 ubiquitin ligase |
PD (AR-JP) |
| SQSTM1 (p62) |
Autophagy receptor |
Various |
| OPTN |
Autophagy receptor |
PD (ALS) |
| BNIP3 |
Receptor-mediated mitophagy |
Cancer, ischemia |
| NIX |
BNIP3 homolog |
Anemia, cancer |
| FUNDC1 |
Hypoxia receptor |
Ischemia |
| Mfn2 |
Mitochondrial fusion |
Neuropathy |
| DRP1 |
Mitochondrial fission |
Various |
- Narendra et al., J Cell Biol (2008) - Parkin is recruited to depolarized mitochondria
- Youle & Narendra, Nat Rev Mol Cell Biol (2011) - Mechanisms of mitophagy
- Lemasters, Hepatology (2005) - Selective mitophagy concept
- Borsche et al., Nat Rev Neurol (2021) - Mitochondria in neurodegeneration
- Lin et al., Neuron (2020) - Mitophagy in brain disorders
- Pickrell & Youle, Neuron (2015) - PINK1 and Parkin in PD
- Matsuda et al., J Cell Biol (2010) - PINK1 stabilized on damaged mitochondria
- Kane et al., J Cell Biol (2014) - PINK1 phosphorylates ubiquitin
- Chen & Dorn, Science (2013) - PINK1 and Parkin on mitochondria
- Lazarou et al., J Cell Biol (2015) - OPTN and NDP52 in mitophagy
- Itakura et al., J Cell Biol (2012) - Mechanisms of mitophagy
- Yang & Klionsky, Autophagy (2010) - Autophagosome-lysosome fusion
- Nixon, Nat Rev Neurosci (2013) - Autophagy in neurodegenerative disease
- Zhang et al., Nature (2016) - BNIP3/NIX in mitophagy
- Liu et al., Nat Cell Biol (2012) - FUNDC1 hypoxia-induced mitophagy
- Chu et al., J Cell Biol (2019) - Cardiolipin externalization in mitophagy
- Belenky et al., Cell (2007) - Mitochondrial function in neurons
- Saxena & Caroni, J Exp Med (2011) - Neuronal vulnerability
- Saxton & Hollenbeck, J Cell Biol (2012) - Mitochondrial transport
- Verstreken et al., Nat Neurosci (2009) - Synaptic mitochondria
- Cai et al., Nat Neurosci (2012) - PINK1 in axonal mitophagy
- Rakovic et al., Hum Mol Genet (2011) - Mitophagy in neurons
- Yoshii et al., J Cell Biol (2011) - Axonal autophagosomes
- Martin-Maestro et al., J Neurosci (2019) - Mitophagy in AD
- Hu et al., Nat Neurosci (2017) - Tau impairs mitophagy
- Dunner et al., Mol Neurodegener (2014) - PINK1 in AD
- Lee et al., Nat Rev Neurol (2010) - Lysosomal dysfunction in AD
- Liu et al., J Alzheimers Dis (2019) - PINK1/Parkin in AD
- Ferrer et al., J Alzheimers Dis (2020) - Amyloid-β and mitophagy
- Xie et al., Nat Neurosci (2019) - Mitophagy enhancement in AD
- Valente et al., Nat Genet (2004) - PINK1 mutations in PD
- Kitada et al., Nature (1998) - Parkin mutations in PD
- Sarkar et al., Nat Rev Neurol (2020) - α-Synuclein and mitophagy
- Schapira et al., Lancet (1989) - Complex I deficiency in PD
- Gao et al., Nat Neurosci (2017) - PINK1 knockout model
- Greene et al., J Neurosci (2003) - Parkin in fly model
- Seibler et al., J Neurosci (2011) - iPSC models of PINK1-PD
- Ferrucci et al., J Neurol Sci (2017) - Mitophagy in ALS
- Squitieri et al., Nat Rev Neurol (2015) - Mitochondria in HD
- Klein et al., Nat Rev Neurol (2006) - PINK1 genetics
- Moore et al., Nat Rev Neurol (2007) - Parkin genetics
- Maruyama et al., Nat Rev Neurol (2010) - OPTN in neurodegeneration
- Freischmidt et al., Nat Neurosci (2015) - TBK1 mutations
- Glick et al., Nat Rev Mol Cell Biol (2010) - Transcriptional regulation
- Wong & Komman, Cell (2013) - PTM regulation
- Ge et al., Nat Rev Neurol (2020) - miRNAs and mitophagy
- Twig et al., EMBO J (2008) - Mitochondrial dynamics
- Gomes et al., J Cell Biol (2011) - Fission and quality control
- Egan et al., Nat Rev Neurol (2011) - AMPK and autophagy
- Dunlop & Eriksson, J Parkinsons Dis (2011) - mTOR and neurodegeneration
- D'Amico et al., Nat Aging (2023) - Urolithin A trials
- Mo et al., Nat Rev Neurol (2022) - Clinical trials
- Hague et al., J Neurosci (2003) - PINK1-/-
- Palikaras et al., Nat Rev Mol Cell Biol (2015) - Mitochondrial biogenesis
- Kim et al., Autophagy (2016) - Proteostasis crosstalk
- Pellegrino et al., Nat Rev Endocrinol (2014) - UPRmt
- Borsche et al., Nat Rev Neurol (2021) - Substantia nigra
- Lin & Beal, Nat Rev Neurol (2006) - Hippocampus and AD
- Shin et al., Brain (2018) - Frontal cortex in PD